{
  "id": "601d76131cb411341a000044",
  "type": "yesno",
  "question": "Is avelumab effective for urothelial carcinoma?",
  "ideal_answer": "Yes. Avelumab is an anti-programmed death-ligand 1 monoclonal antibody that is approved for the treatment of urothelial carcinoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31807039",
    "http://www.ncbi.nlm.nih.gov/pubmed/31286802",
    "http://www.ncbi.nlm.nih.gov/pubmed/33037118",
    "http://www.ncbi.nlm.nih.gov/pubmed/32945632",
    "http://www.ncbi.nlm.nih.gov/pubmed/30004857",
    "http://www.ncbi.nlm.nih.gov/pubmed/29103968",
    "http://www.ncbi.nlm.nih.gov/pubmed/30481100",
    "http://www.ncbi.nlm.nih.gov/pubmed/28585615",
    "http://www.ncbi.nlm.nih.gov/pubmed/31553054",
    "http://www.ncbi.nlm.nih.gov/pubmed/29217288",
    "http://www.ncbi.nlm.nih.gov/pubmed/32146152",
    "http://www.ncbi.nlm.nih.gov/pubmed/29540084",
    "http://www.ncbi.nlm.nih.gov/pubmed/28375787",
    "http://www.ncbi.nlm.nih.gov/pubmed/32135514",
    "http://www.ncbi.nlm.nih.gov/pubmed/31940998",
    "http://www.ncbi.nlm.nih.gov/pubmed/30021426",
    "http://www.ncbi.nlm.nih.gov/pubmed/32762233"
  ],
  "snippets": [
    {
      "text": "ince then, additional checkpoint inhibitors, including avelumab, durvalumab, and nivolumab, have gained approval. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31940998",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avelumab, an anti-programmed death-ligand 1 monoclonal antibody approved for the treatment of metastatic Merkel cell carcinoma and platinum-treated urothelial carcinoma, was initially approved with a 10\u00a0mg/kg weight-based dose. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31553054",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Five new PD-1/PD-L1 checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma (UC): pembrolizumab, atezolizumab, durvalumab, nivolumab, and avelumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32135514",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We reviewed the literature for prospective studies evaluating PD-1/PD-L1 inhibitors in refractory urothelial carcinoma patients, which formed the basis for US Food and Drug Administration approval of 5 different antagonistic antibodies targeting PD-1 or PD-L1 (atezolizumab, durvalumab, avelumab, nivolumab, and pembrolizumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32146152",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nowadays, five immune checkpoint inhibitors blocking PD-1 (pembrolizumab, nivolumab) or PD-L1 (atezolizumab, durvalumab, and avelumab) have been approved by the United States Food and Drug Administration (US FDA) for the first- or second-line use in urothelial carcinoma, based on durable response and manageable safety profiles observed in relevant clinical trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32762233",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RETATION: Avelumab showed antitumour activity in the treatment of patients with platinum-refractory metastatic urothelial carcinoma; a manageable safety profile was reported in all avelumab-treated patients. These",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29217288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "data provide the rationale for therapeutic use of avelumab in metastatic urothelial carcinoma and it has received accelerated US FDA approval in this setting on this basis.FUNDIN",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29217288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33037118",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33037118",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29103968",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. (Fund",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32945632",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "By the emergence of modern immunotherapies with active agents like PD-1 (nivolumab, pembrolizumab) and PD-L1 immune checkpoint blockers (atezolizumab, avelumab, durvalumab), new therapeutic options have become available for the treatment of patients with locally advanced and metastatic urothelial carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28585615",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avelumab, an anti-programmed death-ligand 1 monoclonal antibody approved for the treatment of metastatic Merkel cell carcinoma and platinum-treated urothelial carcinoma, was initially approved with a 10\u00a0mg/kg weight-based dose.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31553054",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "By the emergence of modern immunotherapies with active agents like PD-1 (nivolumab, pembrolizumab) and PD-L1 immune checkpoint blockers (atezolizumab, avelumab, durvalumab), new therapeutic options have become available for the treatment of patients with locally advanced and metastatic urothelial carcinoma. Accor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28585615",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ACQUISITION: Five antibodies including pembrolizumab (PD-L1 antibody), atezolizumab (PD-1 antibody), nivolumab (PD-1 antibody), avelumab and durvalumab (PD-L1 antibodies) have been approved in the treatment of advanced urothelial carcinoma in first- and second-line treatment setting.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30021426",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Avelumab showed antitumour activity in the treatment of patients with platinum-refractory metastatic urothelial carcinoma; a manageable safety profile was reported in all avelumab-treated patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29217288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic UC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28375787",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30004857",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In early 2017, avelumab (BAVENCIO\u00ae), a PD-L1-blocking monoclonal antibody agent, was approved for the treatment of metastatic MCC and UC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30004857",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Avelumab has shown clinical efficacy for metastatic and advanced UC in phase I studies after the failure of platinum-based therapy with a well-tolerated safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31286802",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Avelumab has been approved by the U.S. FDA for the treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma that has progressed during or following treatment with a platinum-based regimen.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30481100",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}